Business Context and Reporting Period
Company: SS Innovations International, Inc. (SSII)
Filing Type: Form 8-K (Current Report)
Date of Report: May 13, 2026
Reporting Period: First quarter ended March 31, 2026
Context: This filing announces the release of financial results for the first quarter of 2026 and the concurrent filing of the Form 10-Q. The company is incorporated in Florida and trades on The Nasdaq Stock Market LLC under the symbol "SSII".
Key Financial Metrics
The provided text is a cover sheet and disclosure framework for the Form 8-K. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific numerical values within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific financial metrics are contained in the referenced press release and Form 10-Q, which are not included in the input text.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. It only confirms the announcement of Q1 2026 results.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes a standard disclaimer regarding forward-looking statements. These statements relate to future events and financial performance, including:
- Preliminary results for the fourth quarter of 2025 and full year 2025.
- Product development timelines.
- Clinical and regulatory timelines.
- Market opportunity and competitive position.
Risks: The company warns that actual results may differ materially from expectations due to known and unknown risks, uncertainties, and other factors. Investors are advised not to place undue reliance on these statements.
Legal Status of Information: Information in Items 2.02 and 7.01 is deemed "furnished" rather than "filed" under the Exchange Act and is not subject to Section 18 liabilities or incorporation by reference into other filings.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net income, and cash flow figures.
- Examine the Form 10-Q filed concurrently for detailed financial statements and notes.
- Verify the specific details regarding Q4 2025 and Full Year 2025 preliminary results mentioned in the forward-looking statements.
- Assess the status of clinical and regulatory timelines for the company's products.
- Confirm the company's liquidity position and debt obligations in the full 10-Q filing.